Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure

被引:68
作者
Norrelund, H.
Wiggers, H.
Halbirk, M.
Frystyk, J.
Flyvbjerg, A.
Botker, H. E.
Schmitz, O.
Jorgensen, J. O. L.
Christiansen, J. S.
Moller, N.
机构
[1] Aarhus Univ Hosp, Aarhus Sygehus, Med Dept Endocrinol & Diabet M, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Skejby Hosp, Dept Cardiol, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, Aarhus Hosp, Inst Expt Clin Res, DK-8000 Aarhus C, Denmark
关键词
glucose metabolism; heart failure; lipid metabolism; muscle metabolism;
D O I
10.1111/j.1365-2796.2006.01663.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. It is well known that chronic heart failure (CHF) is associated with insulin resistance and cachexia, but little is known about the underlying substrate metabolism. The present study was undertaken to identify disturbances of basal glucose, lipid and protein metabolism. Design. We studied eight nondiabetic patients with CHF (ejection fraction 30 +/- 4%) and eight healthy controls. Protein metabolism (whole body and regional muscle fluxes) and total glucose turnover were isotopically assayed. Substrate oxidation were obtained by indirect calorimetry. The metabolic response to exercise was studied by bicycle ergometry exercise. Results. Our data confirm that CHF patients have a decreased lean body mass. CHF patients are characterised by (i) decreased glucose oxidation [glucose oxidation (mg kg(-1) min(-1)): 1.25 +/- 0.09 (patients) vs. 1.55 +/- 0.09 (controls), P < 0.01] and muscle glucose uptake [a - v diff(glucose) (mu mol L-1): -10 +/- 25 (patients) vs. 70 +/- 22 (controls), P < 0.01], (ii) elevated levels of free fatty acids (FFA) [FFA (mmol L-1): 0.72 +/- 0.05 (patients) vs. 0.48 +/- 0.03 (controls), P < 0.01] and 3-hydroxybutyrate and signs of elevated fat oxidation and muscle fat utilization [a - v diff(FFA) (mmol L-1): 0.12 +/- 0.02 (patients) vs. 0.05 +/- 0.01 (controls), P < 0.05] and (iii) elevated protein turnover and protein breakdown [phenylalanine flux (mu mol kg(-1) h(-1)): 36.4 +/- 1.5 (patients) vs. 29.6 +/- 1.3 (controls), P < 0.01]. Patients had high circulating levels of noradrenaline, glucagon, and adiponectin, and low levels of ghrelin. We failed to observe any differences in metabolic responses between controls and patients during short-term exercise. Conclusions. In the basal fasting state patients with CHF are characterized by several metabolic abnormalities which may contribute to CHF pathophysiology and may provide a basis for targeted intervention.
引用
收藏
页码:11 / 21
页数:11
相关论文
共 50 条
[1]   No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia [J].
Altunbas, H ;
Balci, MK ;
Karayalçin, Ü .
ENDOCRINE RESEARCH, 2003, 29 (03) :265-275
[2]   Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].
Anker, SD ;
Negassa, A ;
Coats, AJS ;
Afzal, R ;
Poole-Wilson, PA ;
Cohn, JN ;
Yusuf, S .
LANCET, 2003, 361 (9363) :1077-1083
[3]   Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Maeda, K ;
Kuriyama, H ;
Okamoto, Y ;
Kumada, M ;
Hotta, K ;
Nishida, M ;
Takahashi, M ;
Nakamura, T ;
Shimomura, I ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
CIRCULATION, 2002, 105 (24) :2893-2898
[4]   Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans [J].
Ariyasu, H ;
Takaya, K ;
Tagami, T ;
Ogawa, Y ;
Hosoda, K ;
Akamizu, T ;
Suda, M ;
Koh, T ;
Natsui, K ;
Toyooka, S ;
Shirakami, G ;
Usui, T ;
Shimatsu, A ;
Doi, K ;
Hosoda, H ;
Kojima, M ;
Kangawa, K ;
Nakao, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (10) :4753-4758
[5]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[6]   Control of glucose uptake and release by the liver in vivo [J].
Cherrington, AD .
DIABETES, 1999, 48 (05) :1198-1214
[7]   Exercise limitation in chronic heart failure: Central role of the periphery [J].
Clark, AL ;
PooleWilson, PA ;
Coats, AJS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (05) :1092-1102
[8]   Insulin resistance in chronic heart failure [J].
Coats, AJS ;
Anker, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 :S9-S14
[9]   Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure [J].
Doehner, W ;
Rauchhaus, M ;
Ponikowski, P ;
Godsland, IF ;
von Haehling, S ;
Okonko, DO ;
Leyva, F ;
Proudler, AJ ;
Coats, AJS ;
Anker, SD .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (06) :1019-1026
[10]   DETERMINATION OF CATECHOLAMINES IN RAT-HEART TISSUE AND PLASMA SAMPLES BY LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
ERIKSSON, BM ;
PERSSON, BA .
JOURNAL OF CHROMATOGRAPHY, 1982, 228 (MAR) :143-154